Sign In
Buy EYPT
$12.34
-0.190 (-1.52%)
At Close: Jun 03, 2026
EyePoint announces $175 million stock offering following record surge in share price
05:06pm, Monday, 04'th Dec 2023
EyePoint Pharmaceuticals Inc. EYPT, +177.46% announced Monday afternoon that it has begun an underwritten public offering of $175 million in common stock. The company will also give underwriters the c
Eyepoint Pharmaceuticals stock soars on wet-AMD trial results
12:52pm, Monday, 04'th Dec 2023
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) shares surged 176% to $18.24 in midday trading on Monday after the therapeutics developer announced positive results from a Phase 2 trial of its EYP-1901 tre
Why Is EyePoint Pharmaceuticals (EYPT) Stock Up 187% Today?
11:37am, Monday, 04'th Dec 2023
EyePoint Pharmaceuticals (NASDAQ: EYPT ) stock is rocketing higher on Monday thanks to the company's latest clinical trial results for EYP-1901. A Phase 2 clinical trial of EYP-1901 includes positive
EyePoint Pharmaceuticals' stock soars 362% after company announces positive data from trial of wet AMD treatment
07:40am, Monday, 04'th Dec 2023
EyePoint Pharmaceutics Inc.'s stock EYPT, +5.76% rocketed 362% early Monday, after the company announced positive results from a Phase 2 trial of its EYP-1901 treatment for wet age-related macular deg
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
04:17pm, Sunday, 03'rd Dec 2023
If the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside. To clar
EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2023 Earnings Conference Call Transcript
01:03pm, Wednesday, 01'st Nov 2023
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Conference Cal
EyePoint Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 1, 2023
07:00am, Wednesday, 25'th Oct 2023
WATERTOWN, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w
Why Shares of EyePoint Pharmaceuticals Were Rising Monday
03:20pm, Monday, 11'th Sep 2023
EyePoint reported top-line data on two phase 2 trials for its lead pipeline candidate. The company focuses on serious eye disorders.
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
07:00am, Wednesday, 30'th Aug 2023
WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the live
EyePoint: Well-Funded And Catalyst-Rich, But Not Without Risks
08:31am, Monday, 21'st Aug 2023
EyePoint Pharmaceuticals is developing the EYP-1901 treatment for wet age-related macular degeneration and non-proliferative diabetic retinopathy. Q2 2023 earnings show a decrease in net revenue, but
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
07:00am, Wednesday, 09'th Aug 2023
WATERTOWN, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Lags Revenue Estimates
09:42am, Wednesday, 02'nd Aug 2023
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of $0.41. This compares to loss of $0.52 per share a year ago.
EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023
07:00am, Wednesday, 26'th Jul 2023
WATERTOWN, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w
EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference
07:00am, Wednesday, 31'st May 2023
WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients wi
EyePoint Pharmaceuticals: A Puncher's Chance For Long Acting Eye Disease Drug Success
08:00am, Tuesday, 30'th May 2023
EyePoint is a $200m market cap biotech focused on eye disease. The company's long-acting Durasert technology has been supporting its commercial product, YUTIQ, which earned $28m of revenues in FY22. E
